Benjamin L. Palleiko serves as the President, Chief Business Officer, and Chief Financial Officer at KalVista Pharmaceuticals, Inc., a position he has held since 2016. KalVista is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. In his multifaceted role, Palleiko is responsible for overseeing the company's financial strategies, business development, and operational management. His leadership has been instrumental in guiding KalVista through various stages of growth, including securing funding and advancing their drug development pipeline. Prior to joining KalVista, Palleiko held several senior positions in the biopharmaceutical industry. He was the Chief Financial Officer at Good Start Genetics, a genetic testing company, where he played a key role in scaling the business and establishing strategic partnerships. Before that, he served as the Vice President of Finance and Corporate Development at Agenus Inc., a clinical-stage immuno-oncology company. Palleiko's extensive experience in finance and business development has equipped him with the skills necessary to drive KalVista's success in a competitive industry. Under Palleiko's leadership, KalVista has made significant strides in advancing its lead product candidate, sebetralstat, for the treatment of hereditary angioedema (HAE). His strategic vision has been crucial in navigating the company through clinical trials and regulatory processes. Additionally, Palleiko has been a key figure in securing investments and partnerships that have bolstered KalVista's financial stability and growth potential. His dedication to innovation and excellence continues to position KalVista as a leader in the development of novel treatments for underserved medical conditions.